Skip to main content

Triazolam Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 20, 2024.

Applies to triazolam: oral tablet.

Warning

Oral route (Tablet)

Risks From Concomitant Use With Opioids; Abuse, Misuse, and Addiction; and Dependence and Withdrawal ReactionsConcomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.The use of benzodiazepines, including triazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing triazolam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.The continued use of benzodiazepines, including triazolam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of triazolam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue triazolam or reduce the dosage.

Serious side effects of Triazolam

Along with its needed effects, triazolam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking triazolam:

Less common

Rare

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking triazolam:

Symptoms of overdose

Other side effects of Triazolam

Some side effects of triazolam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Rare

Incidence not known

For Healthcare Professionals

Applies to triazolam: oral tablet.

General

The most commonly reported side effects included drowsiness/sedation, dizziness/lightheadedness, headache, and ataxia.[Ref]

Nervous system

Very common (10% or more): Sedation (up to 19.4%), drowsiness (up to 14%)

Common (1% to 10%): Anterograde amnesia with appropriate/inappropriate behavior, ataxia, concentration difficulty, coordination disorders/impaired coordination, dizziness, headache, impaired equilibrium, lethargy, lightheadedness, memory impairment

Rare (0.01% to 0.1%): Dysesthesia, paresthesia, taste alterations

Frequency not reported: Amnestic symptoms, clouding of consciousness/altered state of consciousness, dysarthria, dystonia, grogginess, slurred speech, somnambulism, somnolence, syncope[Ref]

Complex behaviors, such as "sleep-driving", other behaviors such as preparing and eating food, making phone calls, or having sex, with amnesia for these events, have been reported at therapeutic doses with this medicine.[Ref]

Genitourinary

Very common (10% or more): WBC/high power field (HPF) in urinalysis (up to 11.3%)

Common (1% to 10%): Albuminuria, red blood cells/HPF in urinalysis

Frequency not reported: Bladder trouble, incontinence, menstrual irregularities, urinary retention[Ref]

Hematologic

Very common (10% or more): Low eosinophil count (up to 10.2%)

Common (1% to 10%): High eosinophil count, low monocyte count, low/high basophil count, low/high lymphocyte count, low/high neutrophil count, low/high WBC count

Metabolic

Common (1% to 10%): High bilirubin, increased alkaline phosphatase, low/high creatinine

Frequency not reported: Anorexia[Ref]

Psychiatric

Rebound insomnia (a worsening of sleep following cessation of therapy) has been observed and has sometimes been reported to occur in association with increased daytime anxiety.

Withdrawal symptoms have included agitation, restlessness, anxiety, insomnia, psychosis, delirium, convulsions, tremor, abdominal cramps, blurred vision, vomiting, and sweating.

Worsening of insomnia, depression, or the emergence of new thinking or behavior abnormalities, including suicidal thinking, have emerged during treatment with sedative-hypnotic drugs, including this drug. The frequency and extent to which this drug is associated with adverse behavioral effects is controversial.

One study based on the postmarketing surveillance Spontaneous Reporting System of the FDA has suggested that adverse behavioral reactions have been reported 22 to 99 times more frequently in association with triazolam therapy than with temazepam therapy for insomnia. An increased frequency of adverse behavioral effects was noted to occur most frequently in elderly patients and at higher doses of this drug. The methodology of this study, however, has been questioned on the grounds that spontaneous reports of adverse effects do not necessarily correlate with the incidence of adverse effects.

Other studies and reports have concluded that little evidence exists to support the contention that this drug is associated with a greater risk of adverse behavioral effects than other benzodiazepines (including temazepam).[Ref]

Common (1% to 10%): Anxiety, nervousness

Uncommon (0.1% to 1%): Confusional states, depression, euphoria

Rare (0.01% to 0.1%): Dreaming, insomnia, nightmares

Frequency not reported: Abnormal behavior, abnormal dreams, abuse, acute rage, addiction, aggressiveness/aggression, agitation, agitational state, bizarre behavior, changes in libido, delusions, depersonalization, derealization, disorientation, disorientation in time/place, excitation, hallucinations, inappropriate behavior, irritability, libido disorder, mania, other adverse behavioral effects, paranoia, restlessness, sleep disorder/sleep disturbances, stimulation[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, vomiting

Rare (0.01% to 0.1%): Constipation, diarrhea, dry mouth

Frequency not reported: Abdominal distress, burning tongue, glossitis, stomatitis, tongue discomfort[Ref]

Other

Common (1% to 10%): Tiredness

Uncommon (0.1% to 1%): Pain

Rare (0.01% to 0.1%): Tinnitus, weakness

Frequency not reported: Falling, fatigue, paradoxical reactions[Ref]

Hepatic

Common (1% to 10%): High AST levels

Rare (0.01% to 0.1%): Death (from hepatic failure)

Frequency not reported: Jaundice[Ref]

Death from hepatic failure has been reported in a patient also receiving diuretic drugs.[Ref]

Dermatologic

Uncommon (0.1% to 1%): Pruritus, skin rash

Rare (0.01% to 0.1%): Dermatitis[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Palpitations, tachycardia

Frequency not reported: Chest pain[Ref]

Respiratory

Uncommon (0.1% to 1%): Hiccups

Rare (0.01% to 0.1%): Congestion[Ref]

One study of patients with obstructive sleep apnea has suggested that this drug may increase the maximum apnea duration and lower the minimum oxygen saturation of apneic patients.[Ref]

Musculoskeletal

Uncommon (0.1% to 1%): Cramps

Frequency not reported: Aching limbs, backache, increased muscle spasticity[Ref]

Ocular

Uncommon (0.1% to 1%): Visual disturbances

Frequency not reported: Blepharitis[Ref]

Hypersensitivity

Rare (0.01% to 0.1%): Allergy

Postmarketing reports: Anaphylactic shock, anaphylactoid reaction, allergic edema, angioneurotic edema, hypersensitivity reaction[Ref]

References

1. Product Information. Halcion (triazolam). Pharmacia and Upjohn. 2001;PROD.

2. Cerner Multum, Inc. Australian Product Information.

3. Rothschild AJ. Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psychiatry. 1992;53:69-79.

4. Morris HH, 3d Estes ML. Traveler's amnesia. Transient global amnesia secondary to triazolam. JAMA. 1987;258:945-6.

5. Wysowski DK, Barash D. Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System. Arch Intern Med. 1991;151:2003-8.

6. Andreadis NA, Schirmer RG. Use of spontaneous reporting system data. Arch Intern Med. 1992;152:1527-9.

7. Patterson WM. Triazolam withdrawal. J Clin Psychiatry. 1988;49:369.

8. Weilburg JB, Sachs G, Falk WE. Triazolam-induced brief episodes of secondary mania in a depressed patient. J Clin Psychiatry. 1987;48:492-3.

9. Schneider LS, Syapin PJ, Pawluczyk S. Seizures following triazolam withdrawal despite benzodiazepine treatment. J Clin Psychiatry. 1987;48:418-9.

10. Heritch AJ, Capwell R, Roy-Byrne PP. A case of psychosis and delirium following withdrawal from triazolam. J Clin Psychiatry. 1987;48:168-9.

11. Schogt B, Conn D. Paranoid symptoms associated with triazolam. Can J Psychiatry. 1985;30:462-3.

12. Rush CR, Higgins ST, Hughes JR, Bickel WK. A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers. Psychopharmacology (Berl). 1993;112:407-14.

13. Sullivan RJ, Jr. Respiratory depression requiring ventilatory support following 0.5 mg of triazolam. J Am Geriatr Soc. 1989;37:450-2.

14. Berry RB, Kouchi K, Bower J, Prosise G, Light RW. Triazolam in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1995;151:450-4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.